Expression of β-adrenergic receptor up-regulation is mediated by two different processesOHKUMA, Seitaro; KATSURA, Masashi; SHIBASAKI, Masahiro et al.Brain research. 2006, Vol 1112, pp 114-125, issn 0006-8993, 12 p.Article

A simple spectrophotometric method for the determination of β-blockers in dosage formsAL-GHANNAM, S. M.Journal of pharmaceutical and biomedical analysis. 2006, Vol 40, Num 1, pp 151-156, issn 0731-7085, 6 p.Article

Life-Threatening Flecainide Intoxication in a Young Child Secondary to Medication ErrorD'ALESSANDRO, Lisa Ca; RIEDER, Michael J; GLOOR, Jane et al.The Annals of pharmacotherapy. 2009, Vol 43, Num 9, pp 1522-1527, issn 1060-0280, 6 p.Article

Suspected β-antagonist-induced thrombocytopeniaSTAMM, Pamela L; JENKINS, J. Kimble; VIGRASS, Howard G et al.The Annals of pharmacotherapy. 2005, Vol 39, Num 3, pp 555-558, issn 1060-0280, 4 p.Article

Response to salbutamol in patients with mild asthma treated with nadololHANANIA, N. A; MANNAVA, B; FRANKLIN, A. E et al.The European respiratory journal. 2010, Vol 36, Num 4, pp 963-965, issn 0903-1936, 3 p.Article

Green Tea Ingestion Greatly Reduces Plasma Concentrations of Nadolol in Healthy SubjectsMISAKA, S; YATABE, J; YAMADA, S et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 4, pp 432-438, issn 0009-9236, 7 p.Article

Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis : a pathophysiological interpretationMERKEL, C; BOLOGNESI, M; SACERDOTI, D et al.Alimentary pharmacology & therapeutics. 2005, Vol 22, Num 5, pp 433-439, issn 0269-2813, 7 p.Article

Nadolol inhibits reactive oxygen species generation by leukocytes and linoleic acid oxidationMAGSINO, C. H; HAMOUDA, W; BAPNA, V et al.The American journal of cardiology. 2000, Vol 86, Num 4, pp 443-448, issn 0002-9149Article

PROTON-MAGNETIC-RESONANCE (PMR) ASSAY OF NADOLOL IN DOSAGE FORMMOHAMED ME; TAWAKKOL MS.1981; PHARMAZIE; ISSN 0031-7144; DDR; DA. 1981; VOL. 36; NO 12; PP. 856; BIBL. 3 REF.Article

COLORIMETRIC DETERMINATION OF NADOLOL IN TABLETS.IVASHKIV E.1978; J. PHARM. SCI.; USA; DA. 1978; VOL. 67; NO 7; PP. 1024-1025; BIBL. 4 REF.Article

Penetration of dimyristoylphosphatidylcholine monolayers and bilayers by model β-blocker agents of varying lipophilicityKRILL, S. L; KA YAN LAU; PLACHY, W. Z et al.Journal of pharmaceutical sciences. 1998, Vol 87, Num 6, pp 751-756, issn 0022-3549Article

A propos d'un cas d'intoxication par la Flécaïne® = Case report of flecaine intoxicationANDRE, P; BERGINIAT, N; TRIAUREAU, G et al.Urgences médicales (Paris). 1997, Vol 16, Num 5, pp 205-207, issn 0923-2524Article

NADOLOL, A ONCE DAILY TREATMENT FOR HYPERTENSION MULTI-CENTRE CLINICAL EVALUATIONJACKSON DA.1980; BRIT. J. CLIN. PRACT.; GBR; DA. 1980; VOL. 34; NO 7; PP. 211-221; BIBL. 28 REF.Article

EFFICACITE ET TOLERANCE DU NADOLOL CHEZ LES CORONARIENSABASTADO M; MESNIER JP.1980; MED. INTERNE; FRA; DA. 1980; VOL. 15; NO 2; PP. 123-131; (8 P.)Article

β₁-Adrenergic receptor up-regulation induced by nadolol is mediated via signal transduction pathway coupled to α₁-adrenergic receptorsMIZUNO, Koji; KUROKAWA, Kazuhiro; SHIBASAKI, Masahiro et al.Brain research. 2011, Vol 1414, pp 10-21, issn 0006-8993, 12 p.Article

NADOLOL: ITS USE IN THE PROPHYLACTIC TREATMENT OF MIGRAINERYAN RE; RYAN RE JR; SUDILOVSKY A et al.1983; HEADACHE; ISSN 0017-8748; USA; DA. 1983; VOL. 23; NO 1; PP. 26-31; BIBL. 9 REF.Article

ROLE OF SYMPATHETIC NERVOUS SYSTEM IN NONISCHAEMIC VENTRICULAR ARRHYTHMIASCOURMEL P; ROSENGARTEN MD; LECLERCQ JF et al.1982; BR. HEART J.; ISSN 0007-0769; GBR; DA. 1982; VOL. 47; NO 2; PP. 137-147; BIBL. 17 REF.Article

PRECLINICAL TOXICOLOGIC EVALUATION OF NADOLOL, A NEW BETA -ADRENERGIC ANTAGONISTSIBLEY PL; KEIM GR; KULESZA JS et al.1978; TOXICOL. APPL. PHARMACOL.; USA; DA. 1978; VOL. 44; NO 2; PP. 379-389; BIBL. 13 REF.Article

ANTI-ARRHYTHMIC ACTION OF NADOLOL, A BETA -ADRENERGIC RECEPTOR BLOCKING AGENTEVANS DB; PESCHKA MT; LEE RJ et al.1976; EUROP. J. PHARMACOL.; NETHERL.; DA. 1976; VOL. 35; NO 1; PP. 17-27; BIBL. 1 P. 1/2Article

REDISTRIBUTION OF CARDIAC OUTPUT TO THE KIDNEYS DURING ORAL NADOLOL ADMINISTRATIONTEXTOR SC; FOUAD FM; BRAVO EL et al.1982; NEW ENGLAND JOURNAL OF MEDICINE; ISSN 0028-4793; USA; DA. 1982; VOL. 307; NO 10; PP. 601-605; BIBL. 22 REF.Article

FLUOROMETRIC DETERMINATION OF NADOLOL IN HUMAN SERUM AND URINE.IVASHKIV E.1977; J. PHARM. SCI.; U.S.A.; DA. 1977; VOL. 66; NO 8; PP. 1168-1172; BIBL. 23 REF.Article

Design of pseudo-simulated moving bed process with multi-objective optimization for the separation of a ternary mixture: Linear isothermsJU WEON LEE; WANKAT, Phillip C.Journal of chromatography. 2010, Vol 1217, Num 20, pp 3418-3426, issn 0021-9673, 9 p.Article

Chiral separation and modeling of the three-chiral-center β-blocker drug nadolol by simulated moving bed chromatographyXIN WANG; CHI BUN CHING.Journal of chromatography. 2004, Vol 1035, Num 2, pp 167-176, issn 0021-9673, 10 p.Article

Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trialGARCIA-PAQAN, J. C; VILLANUEVA, C; ALBILLOS, A et al.Gut. 2009, Vol 58, Num 8, pp 1144-1150, issn 0017-5749, 7 p.Article

Severity, time, and β-adrenergic receptor involvement in surgery-induced immune alterationsNELSON, C. J; LYSLE, D. T.The Journal of surgical research. 1998, Vol 80, Num 2, pp 115-122, issn 0022-4804Article